Avaxia Biologics Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 15

Employees

  • Latest Deal Type
  • M&A

  • Investors
  • 1

Avaxia Biologics General Information

Description

Operator of a clinical-stage biopharmaceutical platform intended to develop gut-targeted therapeutics. The company's platform uses a proprietary oral antibody to develop gut-targeted therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis, enabling patients with inflammatory bowel disease, diabetes and obesity to improve treatment.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 128 Spring Street
  • Suite 620
  • Lexington, MA 02421
  • United States
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Acquirer
Circle33
Vertical(s)
Corporate Office
  • 128 Spring Street
  • Suite 620
  • Lexington, MA 02421
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Avaxia Biologics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Merger/Acquisition 01-Jan-2018 Completed Generating Revenue
11. Later Stage VC (Series B1) 21-Jul-2015 Completed Generating Revenue
10. Grant 21-Jan-2015 Completed Generating Revenue
9. Later Stage VC (Series B) 24-May-2013 Completed Generating Revenue
8. Later Stage VC (Series A) 01-Jun-2012 Completed Product Development
7. Grant 19-Mar-2012 Completed Product Development
6. Later Stage VC 01-Jun-2011 Completed Clinical Trials - Phase 1
5. Grant 10-Mar-2011 Completed Clinical Trials - Phase 1
4. Grant 04-Nov-2010 $244K Completed Clinical Trials - Phase 1
3. Grant 01-Apr-2010 $213K Completed Clinical Trials - Phase 1
To view Avaxia Biologics’s complete valuation and funding history, request access »

Avaxia Biologics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B1
Series B
Series A 3,000,000 $0.000100 8% $1.78 $1.78 1x $1.78 20.17%
To view Avaxia Biologics’s complete cap table history, request access »

Avaxia Biologics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage biopharmaceutical platform intended to develop gut-targeted therapeutics. The company's pla
Drug Delivery
Lexington, MA
15 As of 2015

South San Francisco, CA
 

Lexington, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Avaxia Biologics Competitors (22)

One of Avaxia Biologics’s 22 competitors is Neurona Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Neurona Therapeutics Formerly VC-backed South San Francisco, CA
Aldeyra Therapeutics Formerly VC-backed Lexington, MA
OrphoMed Venture Capital-Backed San Francisco, CA
Phathom Pharmaceuticals Formerly VC-backed Florham Park, NJ
Brainstorm Cell Therapeutics Corporation New York, NY
You’re viewing 5 of 22 competitors. Get the full list »

Avaxia Biologics Patents

Avaxia Biologics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2012290104-A1 Bovine polyclonal antibody specific for human tnf Inactive 01-Aug-2011
CA-2843315-A1 Bovine polyclonal antibody specific for human tnf Inactive 01-Aug-2011
EP-2739650-A2 Bovine polyclonal antibody specific for human tnf Inactive 01-Aug-2011
EP-2739650-A4 Bovine polyclonal antibody specific for human tnf Inactive 01-Aug-2011
WO-2013019889-A2 Bovine polyclonal antibody specific for human tnf Inactive 01-Aug-2011 C07K16/241
To view Avaxia Biologics’s complete patent history, request access »

Avaxia Biologics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Avaxia Biologics Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
AbbVie Ventures Corporate Venture Capital Minority
Ariel Savannah Angel Partners Angel Group Minority
Beacon Angels Angel Group Minority
Beta Fund Venture Capital Minority
Boston Harbor Angels Angel Group Minority
You’re viewing 5 of 16 investors. Get the full list »

Avaxia Biologics FAQs

  • When was Avaxia Biologics founded?

    Avaxia Biologics was founded in 2005.

  • Where is Avaxia Biologics headquartered?

    Avaxia Biologics is headquartered in Lexington, MA.

  • What is the size of Avaxia Biologics?

    Avaxia Biologics has 15 total employees.

  • What industry is Avaxia Biologics in?

    Avaxia Biologics’s primary industry is Drug Delivery.

  • Is Avaxia Biologics a private or public company?

    Avaxia Biologics is a Private company.

  • What is Avaxia Biologics’s current revenue?

    The current revenue for Avaxia Biologics is .

  • How much funding has Avaxia Biologics raised over time?

    Avaxia Biologics has raised $23.7M.

  • Who are Avaxia Biologics’s investors?

    AbbVie Ventures, Ariel Savannah Angel Partners, Beacon Angels, Beta Fund, and Boston Harbor Angels are 5 of 16 investors who have invested in Avaxia Biologics.

  • Who are Avaxia Biologics’s competitors?

    Neurona Therapeutics, Aldeyra Therapeutics, OrphoMed, Phathom Pharmaceuticals, and Brainstorm Cell Therapeutics are some of the 22 competitors of Avaxia Biologics.

  • When was Avaxia Biologics acquired?

    Avaxia Biologics was acquired on 01-Jan-2018.

  • Who acquired Avaxia Biologics?

    Avaxia Biologics was acquired by Circle33.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process